• Publications
  • Influence
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg ofAtorvaston per day, with a greater incidence of elevated aminotransferase levels. Expand
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
It is demonstrated that genetic studies of glycemic traits can identify type 2 diabetes risk loci, as well as loci containing gene variants that are associated with a modest elevation in glucose levels but are not associated with overt diabetes. Expand
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. Expand
Effects of torcetrapib in patients at high risk for coronary events.
Although there was evidence of an off-target effect of torcetrapib, it cannot rule out adverse effects related to CETP inhibition, and the trial was terminated prematurely because of an increased risk of death and cardiac events. Expand
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. Expand
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Small-molecule inhibitors of CETP have now been tested in human subjects and shown to increase the concentration of HDL cholesterol while decreasing that of LDL cholesterol and apoB, and test the hypothesis in randomized trials of humans that pharmacological inhibition of CETp retards the development of atherosclerosis. Expand
Antiinflammatory Properties of HDL
There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these isExpand
Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway.
  • P. Xia, J. Gamble, +7 authors M. Vadas
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 24 November 1998
It is demonstrated that the SKase pathway through the generation of S1P is critically involved in mediating TNFalpha-induced endothelial cell activation. Expand
Meta-analysis and imputation refines the association of 15q25 with smoking quantity
TheOx-GSK study established to perform a genome-wide meta-analysis of SNP association with smoking-related behavioral traits confirmed an effect on smoking quantity at a locus on 15q25 that includes CHRNA5, CHRNA3 and CHRNB4, three genes encoding neuronal nicotinic acetylcholine receptor subunits. Expand